ICD-11 code 2C61.1 refers to invasive lobular carcinoma of the breast, which is a type of breast cancer that starts in the lobules of the breast. Lobular carcinoma is a less common form of breast cancer compared to invasive ductal carcinoma, but it can still be aggressive and have a high risk of spreading to other parts of the body.
Invasive lobular carcinoma of the breast is characterized by abnormal cells that have broken through the lobule and invaded surrounding breast tissue. It can sometimes be harder to detect on mammograms than invasive ductal carcinoma, as the cells tend to grow in a single-file pattern rather than forming a solid mass. Lobular carcinoma can also occur in both breasts or develop in multiple areas of the breast simultaneously.
Treatment for invasive lobular carcinoma of the breast may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy, depending on the stage of the cancer and other individual factors. Patients with lobular carcinoma may be monitored closely for any signs of recurrence or metastasis, as the cancer has a higher tendency to spread to the lymph nodes, bones, or other organs. It is important for individuals diagnosed with lobular carcinoma to work closely with their healthcare team to determine the most effective treatment plan for their specific situation.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The equivalent SNOMED CT code for the ICD-11 code 2C61.1, which denotes Invasive lobular carcinoma of the breast, is 367375009. This SNOMED CT code specifically identifies the presence of invasive lobular carcinoma within the breast tissue, providing a standardized terminology for healthcare professionals to accurately document and exchange information related to this specific type of breast cancer.
By using a standardized coding system like SNOMED CT, healthcare providers can ensure consistency in recording patient information across different healthcare settings. This enables better communication among healthcare professionals and facilitates data sharing for research and quality improvement initiatives related to breast cancer treatment and outcomes.
Having an equivalent SNOMED CT code for the ICD-11 code 2C61.1 streamlines the process of data management and analysis in the healthcare industry, ultimately leading to improved patient care and outcomes for individuals with invasive lobular carcinoma of the breast.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Invasive lobular carcinoma of the breast, classified as 2C61.1 in the International Classification of Diseases, is a type of breast cancer that accounts for about 10-15% of all cases. This specific form of carcinoma arises from the lobules of the breast, which are the milk-producing glands. Unlike invasive ductal carcinoma, which forms in the ducts of the breast, invasive lobular carcinoma tends to spread more diffusely within the breast tissue.
Symptoms of invasive lobular carcinoma can vary but often include a palpable lump in the breast or thickening of the breast tissue. Other signs may include changes in the skin over the breast, such as dimpling or redness, as well as nipple changes such as inversion or discharge. In some cases, patients may experience breast pain or discomfort, though this is not a common symptom of invasive lobular carcinoma.
Invasive lobular carcinoma can also present with less specific symptoms that may be mistaken for other conditions. These can include breast asymmetry, breast swelling, or a feeling of fullness in the breast. It is important for individuals who notice any changes in their breast tissue to consult with a healthcare provider for further evaluation, as early detection and treatment can significantly improve outcomes for patients with breast cancer.
🩺 Diagnosis
Diagnosis of 2C61.1, Invasive lobular carcinoma of the breast, is typically achieved through a combination of imaging studies, physical exams, and biopsies.
Imaging studies commonly used in the diagnosis of this condition include mammograms, ultrasounds, and MRIs. These tests can help identify any abnormal growths or masses in the breast tissue.
Physical exams performed by healthcare providers may also reveal lumps or changes in the breast tissue that could indicate the presence of invasive lobular carcinoma. Patients may be asked to undergo further testing if any concerning findings are noted during the exam.
Biopsies are often necessary to definitively diagnose invasive lobular carcinoma. A biopsy involves removing a small sample of tissue from the affected area and examining it under a microscope to check for the presence of cancer cells. Various biopsy techniques may be used, including fine-needle aspiration, core needle biopsy, or surgical biopsy.
💊 Treatment & Recovery
Treatment for 2C61.1, or invasive lobular carcinoma of the breast, typically involves a combination of surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. The primary goal of treatment is to remove the cancer, prevent its recurrence, and reduce the risk of metastasis to other parts of the body.
Surgery is often the first-line treatment for invasive lobular carcinoma, with options including lumpectomy (removal of the tumor and surrounding tissue) or mastectomy (removal of the entire breast). Lymph node dissection may also be performed to determine the extent of the cancer’s spread.
Following surgery, radiation therapy may be recommended to target any remaining cancer cells in the breast or nearby lymph nodes. Chemotherapy, hormone therapy, or targeted therapy may also be prescribed depending on the characteristics of the tumor and the patient’s overall health. These treatments are aimed at killing cancer cells, blocking their growth, or reducing the risk of recurrence.
Recovery from treatment for 2C61.1 can vary depending on the extent of the disease, the type of treatment received, and individual factors such as age and overall health. Patients may experience side effects from surgery, radiation, or systemic therapies, including fatigue, pain, nausea, and hair loss. Supportive care such as physical therapy, counseling, and follow-up appointments with healthcare providers can help manage these side effects and support recovery. Regular monitoring and surveillance are also important to detect any signs of recurrence or metastasis.
🌎 Prevalence & Risk
In the United States, invasive lobular carcinoma of the breast, classified as 2C61.1 in the International Classification of Diseases, is the second most common type of breast cancer, accounting for about 10-15% of all cases. It typically affects women over the age of 60 and is more likely to be estrogen receptor-positive than other types of breast cancer. The prevalence of 2C61.1 in the United States has been steadily increasing in recent years, likely due to a combination of factors such as improved detection methods and an aging population.
In Europe, the prevalence of 2C61.1 varies by region, with higher rates reported in countries with older populations such as Italy and Germany. Invasive lobular carcinoma of the breast is generally more common in Western European countries compared to Eastern European countries. The overall prevalence of 2C61.1 in Europe is similar to that in the United States, with approximately 10-15% of all breast cancer cases being classified as invasive lobular carcinoma.
In Asia, the prevalence of 2C61.1 is lower than in Western countries, accounting for only 5-10% of all breast cancer cases. However, the incidence of invasive lobular carcinoma of the breast is increasing in many Asian countries, particularly in urban areas with changing lifestyles and aging populations. In Japan, for example, the prevalence of 2C61.1 has been rising steadily in recent years, reflecting trends seen in other developed Asian countries.
In Australia, the prevalence of 2C61.1 is similar to that in Western countries, with invasive lobular carcinoma of the breast accounting for about 10-15% of all breast cancer cases. The incidence of 2C61.1 in Australia has been relatively stable over the past decade, likely due to improvements in early detection and treatment options. Overall, the prevalence of invasive lobular carcinoma of the breast, classified as 2C61.1, varies by region and population demographics, but it remains an important subtype of breast cancer worldwide.
😷 Prevention
Preventing 2C61.1 (Invasive lobular carcinoma of the breast) involves taking several proactive steps to reduce the risk of developing this type of cancer. One key factor in preventing invasive lobular carcinoma is maintaining a healthy lifestyle. This includes eating a balanced diet rich in fruits and vegetables, exercising regularly, and avoiding tobacco and excessive alcohol consumption.
Regular screening for breast cancer is essential in preventing invasive lobular carcinoma. Women should follow the recommended guidelines for mammograms and clinical breast exams based on their age and family history. Early detection of breast cancer, including invasive lobular carcinoma, can lead to better treatment outcomes and a higher likelihood of survival.
Being aware of one’s family history of breast cancer can also help in preventing invasive lobular carcinoma. Women with a family history of breast cancer may be at higher risk of developing the disease themselves. In these cases, healthcare providers may recommend additional screening or preventive measures, such as genetic testing or prophylactic surgery, to reduce the risk of developing breast cancer.
Maintaining a healthy body weight and hormone levels can also play a role in preventing invasive lobular carcinoma of the breast. Obesity and elevated hormone levels, such as estrogen, have been linked to an increased risk of breast cancer. By maintaining a healthy weight and lifestyle, individuals can help reduce their risk of developing invasive lobular carcinoma and other types of breast cancer.
🦠 Similar Diseases
One disease similar to invasive lobular carcinoma of the breast (2C61.1) is invasive ductal carcinoma of the breast (2C61.0). This disease is characterized by cancer cells that form in the milk ducts and invade nearby breast tissue. Invasive ductal carcinoma is the most common type of breast cancer, accounting for about 70-80% of cases.
Another related disease is ductal carcinoma in situ (DCIS) of the breast (2C61.2). DCIS is a non-invasive form of breast cancer where abnormal cells are found in the lining of a milk duct but have not spread to surrounding breast tissue. Despite being non-invasive, DCIS has the potential to become invasive if left untreated.
A third disease similar to invasive lobular carcinoma is metastatic breast cancer (2C80.9). This disease occurs when breast cancer cells spread to other parts of the body, such as the bones, lungs, liver, or brain. Metastatic breast cancer is considered advanced or stage IV breast cancer and is generally incurable, though treatments can help manage symptoms and prolong life expectancy.